



February 7, 2007

Peregrine Pharmaceuticals to Present at BIO CEO & Investor Conference 2007

- Presentation to Be Webcast Live on Company's Website -

TUSTIN, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company developing targeted therapeutics for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that senior management will present at the BIO CEO & Investor Conference 2007 on Wednesday, February 14, 2007 at 12:00 pm EST. The conference will be held at the Waldorf Astoria Hotel in New York City.

Peregrine CEO and president Steven W. King will provide a review of recent corporate developments.

Mr. King's presentation will be webcast live and can be accessed by visiting the Investor Relations section of Peregrine's website at www.peregrineinc.com. A replay will be available on the Peregrine website and archived for approximately 30 days.

For more information about this conference, please visit:

<http://ceo.bio.org/opencms/ceo/2007/index.jsp>

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing five separate clinical trials in cancer and HCV infection with its lead product candidates bavituximab and Cotara®; in the U.S. and India. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contacts:

GendeLLindheim BioCom Partners

Investors

info@peregrineinc.com

(800) 987-8256

Media

Barbara Lindheim

(212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.

-0-

02/07/2007

/CONTACT: Investors, +1-800-987-8256, info@peregrineinc.com, or Media, Barbara Lindheim, +1-212-918-4650, both of GendeLLindheim BioCom Partners, for Peregrine Pharmaceuticals, Inc./

/Web site: <http://ceo.bio.org/opencms/ceo/2007/index.jsp> /

/Web site: <http://www.peregrineinc.com> /

(PPHM)

CO: Peregrine Pharmaceuticals, Inc.

ST: California, New York

IN: HEA MTC BIO FIN

SU: TDS

LP

-- LAW059 --

1741 02/07/2007 07:00 EST <http://www.prnewswire.com>